Lipegfilgrastim (Lonquex®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001443
English
Authors' recommendations:
Lipegfilgrastim (Lonquex®) is recommended as an option for restricted use within NHS Wales for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Lipegfilgrastim (Lonquex®) should be restricted for use where a long-acting granulocyte colony-stimulating factor (G-CSF) is appropriate. Lipegfilgrastim (Lonquex®) is not recommended for use within NHS Wales outside of this subpopulation.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1297
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Neutropenia
- Febrile Neutropenia
- Adult
- Neoplasms
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.